The research and production company Microkhim, which is a dynamically developing company that has traditionally specialized in the production of cardiac drugs, has begun developing the first domestic drug for treating coronavirus.
In particular, the company’s scientific departments began developing a generic copy of the antiviral drug “AVIGAN”, also known under such trade names as “Favipiravir” and T-705.
The original drug was developed in Japan in 2014, in 2015 it passed the 3rd phase of clinical trials in the United States. At the same time, it was tested during an epidemic in Wuhan and approved for experimental use in Italy against COVID-19.
The company’s management believes that “in a relatively short period of time, Ukraine is able to create its own generic base of drugs that will not be inferior in effectiveness and safety to the original drugs for treating coronavirus. Moreover, the other day the Verkhovna Rada of Ukraine adopted a number of very important amendments to the legislation governing the acceleration of registration procedures. But! The main thing is that this time the changes work in favor of the national producer and the state of Ukraine as a whole!”
“For the reproduction and confirmation of the bioequivalence of the Ukrainian drug for COVID-19 it will take some time. But in the case of the production of drugs by domestic pharmaceutical companies, we can count on a more favorable solution to the situation than with the supply option by foreign firms. During this rush time, the supply of low-quality drugs at inflated prices by foreign companies is much more likely than usual. Production at the facilities of Ukrainian plants is the only possible option to close peak needs and keep the situation within the real economic framework, ”emphasizes Igor Pogromskyi, CEO of Microkhim.
At the moment, it is still difficult to predict the price of the drug for the retail consumer, this will depend on many factors. First of all, now it is dictated by unreasonably high prices for the substance abroad.
In this regard, Igor Pogromskyi emphasizes that “… even in the worst case, when the price of a substance remains excessively high and determines the price of a finished drug, the country will pay much more – if again lobbyists of international pharmaceutical companies will determine the state procurement policy, and we will buy medicines abroad. ”
Microkhim plans to enter the final straight – the release and first deliveries of the finished product within six months, which is a case unprecedented for our country. However, the company’s team is ready to switch to an enhanced mode of work at this difficult time for all of us.